Gestone

/ Ferring Pharmaceuticals

Gestone is given by intramuscular injection. It should be injected deep into the buttock, rather than the thigh or deltoid, using a 1.5 inch (3.8) needle. This site has ample fat cells where a depot of progesterone can be formed for slow release. Dysfunctional uterine bleeding: 5-10mg daily for 5-10 days until 2 days before anticipated onset of menstruation.

Gestone is indicated for the treatment of dysfunctional uterine bleeding. In selected cases as an adjunct to successful treatment of infertility with techniques such as invitro fertilisation (IVF) or gamete intrafallopian
transfer (GIFT) in order to facilitate uterine implantation of the fertilised ovum.

Hypersensitivity to progestins, undiagnosed vaginal bleeding, missed or incomplete abortion, history of thrombo-embolism, mammary or genital
tract carcinoma, thrombo-phlebitis, cerebral haemorrhage, marked hepatic dysfunction.
Contraindicated as a diagnostic test for pregnancy.

There is no absolute proof that progesterone treatment is effective in the maintenance of pregnancy. No clear cut evidence was shown proving the existence of a relation between the use of the preparation and the appearance of defections above the normal rate found in the population.

Breakthrough bleeding, change in menstrual flow, amenorrhoea, changes in cervical  erosion and secretions, breast changes, oedema, weight gain, catabolism, cholestatic jaundice, allergic reactions and rashes, acne, chloasma, mental depression, pyrexia, insomnia, somnolence, nausea, alopecia, hirsutism, local reactions at site of injection.

Gestone may interfere with the effects of bromocriptine. Gestone may affect the
result of laboratory tests of hepatic and/or endocrine functions. Gestone may raise the plasma concentration of cyclosporin.

Pregnancy: Gestone may be used to maintain pregnancy where there is deficient production of endogenous progesterone from the corpus luteum. It should not be necessary to administer Gestone once there is adequate secretion of placental progesterone.
Lactation: Detectable amounts of progesterone enter the breast milk. As the effect on the suckling infant has not been determined, the use of Gestone during lactation is not recommended.

This is unlikely and is not expected to produce any adverse effects. Treatment is observed and, if necessary, symptomatic and supportive measures should be provided.